Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)

[email protected]
Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor)
Trade Name
Orphan Indication Acute lymphoblastic leukemia
USA Market Approval USA
USA Designation Date 2014-11-13 00:00:00
Sponsor Juno Therapeutics, Inc.;307 Westlake Ave. N., St. 300;Seattle, Washington, 98109
Related Access Program
Novartis Pharmaceuticals – Acute Lymphoblastic Leukemia University of California, San Francisco – Acute Lymphoblastic Leukemia ERYtech Pharma – Acute Lymphoblastic Leukemia University of California, San Francisco – Acute lymphoblastic leukemia ERYtech Pharma – Acute lymphoblastic leukemia Amgen – Acute lymphoblastic leukemia